| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib
|
Penel, Nicolas
|
|
|
126 |
C |
p. 45-55
|
artikel
|
| 2 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas
|
Cote, Gregory M.
|
|
|
126 |
C |
p. 21-32
|
artikel
|
| 3 |
Cervical cancer mortality in young adult European women
|
Wojtyla, Cezary
|
|
|
126 |
C |
p. 56-64
|
artikel
|
| 4 |
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
|
Garbe, Claus
|
|
|
126 |
C |
p. 141-158
|
artikel
|
| 5 |
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
|
Garbe, Claus
|
|
|
126 |
C |
p. 159-177
|
artikel
|
| 6 |
Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
|
Samuel, E.
|
|
|
126 |
C |
p. 104-105
|
artikel
|
| 7 |
Hyperprogression upon immunotherapy: A chance for (hyper-)progress
|
Houot, Roch
|
|
|
126 |
C |
p. 139-140
|
artikel
|
| 8 |
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
|
Bagratuni, Tina
|
|
|
126 |
C |
p. 125-135
|
artikel
|
| 9 |
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition
|
Boers, Jorianne
|
|
|
126 |
C |
p. 11-20
|
artikel
|
| 10 |
Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases
|
Sugihara, Yuriko
|
|
|
126 |
C |
p. 91-92
|
artikel
|
| 11 |
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
|
Donskov, Frede
|
|
|
126 |
C |
p. 1-10
|
artikel
|
| 12 |
Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy
|
Wang, Peng-Fei
|
|
|
126 |
C |
p. 136-138
|
artikel
|
| 13 |
Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma
|
Batlevi, Connie L.
|
|
|
126 |
C |
p. 78-90
|
artikel
|
| 14 |
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma
|
Decaudin, Didier
|
|
|
126 |
C |
p. 93-103
|
artikel
|
| 15 |
Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer
|
Clatot, Florian
|
|
|
126 |
C |
p. 116-124
|
artikel
|
| 16 |
Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome
|
Saito, Susumu
|
|
|
126 |
C |
p. 74-77
|
artikel
|
| 17 |
Reviewers 2019
|
|
|
|
126 |
C |
p. 178
|
artikel
|
| 18 |
The CXCR2/CXCL2 signalling pathway – An alternative therapeutic approach in high-grade glioma
|
Acker, Güliz
|
|
|
126 |
C |
p. 106-115
|
artikel
|
| 19 |
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
|
Pondé, Noam
|
|
|
126 |
C |
p. 65-73
|
artikel
|
| 20 |
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
|
Ascierto, Paolo A.
|
|
|
126 |
C |
p. 33-44
|
artikel
|
Tijdschrift beschrijving